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Abstract
Background: Autism is a neurodevelopmental disorder characterized by impairments in social interaction and
deficits in verbal and nonverbal communication, together with the presence of repetitive behaviors or a limited
repertoire of activities and interests. The causes of autism are currently unclear. In a previous study, we determined
that 21% of children with autism have plasma autoantibodies that are immunoreactive with a population of
neurons in the cerebellum that appear to be Golgi cells, which are GABAergic interneurons.
Methods: We have extended this analysis by examining plasma immunoreactivity in the remainder of the brain. To
determine cell specificity, double-labeling studies that included one of the calcium-binding proteins that are
commonly colocalized in GABAergic neurons (calbindin, parvalbumin or calretinin) were also carried out to
determine which GABAergic neurons are immunoreactive. Coronal sections through the rostrocaudal extent of the
macaque monkey brain were reacted with plasma from each of seven individuals with autism who had previously
demonstrated positive Golgi cell staining, as well as six negative controls. In addition, brain sections from adult
male mice were similarly examined.
Results: In each case, specific staining was observed for neurons that had the morphological appearance of
interneurons. By double-labeling sections with plasma and with antibodies directed against g-aminobutyric acid
(GABA), we determined that all autoantibody-positive neurons were GABAergic. However, not all GABAergic
neurons were autoantibody-positive. Calbindin was colabeled in several of the autoantibody-labeled cells, while
parvalbumin colabeling was less frequently observed. Autoantibody-positive cells rarely expressed calretinin.
Sections from the mouse brain processed similarly to the primate sections also demonstrated immunoreactivity to
interneurons distributed throughout the neocortex and many subcortical regions. Some cell populations stained in
the primate (such as the Golgi neurons in the cerebellum) were not as robustly immunoreactive in the mouse
brain.
Conclusions: These results suggest that the earlier report of autoantibody immunoreactivity to specific cells in the
cerebellum extend to other regions of the brain. Further, these findings confirm the autoantibody-targeted cells to
be a subpopulation of GABAergic interneurons. The potential impact of these autoantibodies on GABAergic
disruption with respect to the etiology of autism is discussed herein.
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Background
Autism is a lifelong neurodevelopmental disorder that is
diagnosed in early childhood and is characterized by a
core deficit in social interaction with impairments in
communication, stereotypical movements and restricted
behaviors [1]. Converging evidence over the past 40
years indicates that immune dysfunction may be an
important factor contributing to the development of a
subset of cases of autism [2-4]. Several studies have
shown peripheral immune abnormalities in patients with
autism [5-7]. There is provocative evidence for an
ongoing inflammatory response in some individuals with
autism [8,9].
The possibility has been raised that some forms of
autism may be due to an autoimmune process [10].
There are a number of precedents for autoimmune dis-
eases of the central nervous system. The best known
among these are multiple sclerosis [11,12] and Syden-
ham’s chorea [13,14]. The potential for an autoimmune
etiology with respect to psychiatric disorders, including
the pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections, remains intri-
guing but controversial [14].
A number of reports have identified antibodies in
individuals with autism that are directed against several
central nervous system proteins. These include glial and
neuron-axon filament proteins [15] (but see [16]), mye-
lin basic protein [17] (but see [18]), serotonin receptor
[19], nerve growth factor [20], cerebellar peptides [21],
brain-derived neurotrophic factor [22], brain endothelial
cells [23] and the caudate nucleus [24]. We have
described an increased incidence of autoantibodies to
brain proteins in autism compared with controls [25].
In a previous study [26], we used Western blot analy-
sis and tissue immunohistochemistry to investigate the
presence of autoantibodies to cerebellar tissue. Using
Western blot analysis, we found that the plasma of 21%
of individuals with autism demonstrated immunoreactiv-
ity to a protein of approximately 52 kDa from the
human cerebellum that was present in only 2% of typi-
cally developing controls. When these plasma samples
were then used as primary antibody sources for tissue
immunohistochemistry using sections from the macaque
monkey brain, 21% of the samples from children with
autism spectrum disorder (ASD) compared to 0% of
typically developing controls demonstrated intense
immunoreactivity to what were morphologically deter-
mined to be Golgi cells of the cerebellum. This study
utilized sections from the cerebellum based on early
data that the cerebellum was preferentially involved in
autism. However, it is now clear that autism affects
many brain regions [27], and the question arises
whether the autoantibodies present in autistic
individuals identify a broader class of neurons that are
distributed throughout the brain. Thus, to build upon
our previous findings, in the current study we used
plasma from the same individuals who demonstrated
positive cerebellar Golgi cell immunoreactivity to stain
tissue sections from the full rostrocaudal extent of the
macaque monkey brain. To evaluate conservation of the
target antigens, we also examined brain sections from
adult male mice. We were particularly interested in
determining whether the autoantibody immunoreactivity
would identify neurons from disparate brain regions and
whether the identified neurons would have any unifying
morphological features.
Methods
Participants and sample collection
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki [28] and was
approved by the Institutional Review Board of the Uni-
versity of California-Davis School of Medicine. All parti-
cipants enrolled in the study had written informed
consent provided by their parents and provided consent
to participate if developmentally able. Subjects for this
study were enrolled through the Medical Investigations
of Neurodevelopmental Disorders (M.I.N.D.) Institute
clinic. The current study was designed to be a detailed
follow-up of our previous study that described the pre-
sence of Golgi cell immunoreactivity in the plasma of a
subpopulation of children with autism [26]. Our current
study population consisted of a subgroup of children
previously diagnosed on the autism spectrum (n = 7)
(age range, 2.5 to 7 years) who showed reactivity to an
approximately 52-kDa protein in the cerebellum as
determined by Western blot analysis as well as on the
basis of intense immunoreactivity to Golgi cells of the
cerebellum in the cynomolgus monkey (Macaca fascicu-
laris). We also examined seven participants from our
previous study who were diagnosed on the autism spec-
trum but did not show immunoreactivity to monkey
brain sections. Our control population consisted of typi-
cally developing children with an absence of reactivity
to both the 52-kDa protein and to neurons of the cyno-
molgus monkey brain (n = 6) (age range, 2.5 to 8 years).
Any participants in the control group who were above
criteria in either the Autism Diagnostic Interview-
Revised (ADI-R) or the Autism Diagnostic Observation
Schedule (ADOS) [1,29-31] were excluded. Samples
from children with ASD with an absence of reactivity
detected by both Western blot analysis and immunohis-
tochemical staining were also examined. A diagnosis of
ASD was confirmed in all participants on the basis of
the ADI-R and ADOS score. The final ASD status is
defined as meeting criteria on the communication, social
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interaction and repetitive behavior domains of the ADI-
R with onset prior to 36 months of age and scoring at
or above the social plus communication cutoff for aut-
ism on the ADOS module 1 or 2. The Social Communi-
cation Questionnaire [32] was used to screen for
characteristics of ASD among the typically developing
controls. Children who scored above the screening cut-
off were fully assessed using the ADI-R and ADOS.
Animals and fixation
Nonhuman primate tissue
We choose nonhuman primate tissue as our antigen
source because of the highly conserved nature of auto-
antigens as well as the similar but compressed neurode-
velopment of rhesus monkeys compared with humans
[33]. All procedures were carried out under an approved
University of California-Davis Institutional Animal Care
and Use Protocol and strictly adhered to National Insti-
tutes of Health policies on primate animal subjects. The
brain sections were obtained from two different male
adult cynomolgus macaques (Macaca fascicularis): one
was 9 years old and the other was 15 years, 4 months
old at the time they were killed. The brains from these
animals had been used for neural tract tracing studies,
and library sections were used for the present study. No
animals were killed expressly for these studies. The sec-
tions were obtained from animals for which no health
problems were reported.
Tissue fixation and histological processing were per-
formed according to procedures described previously
[34]. Briefly, the animals were deeply anesthetized and
perfused intracardially with 1% paraformaldehyde in 0.1
M phosphate buffer (pH 7.4) at 4°C at a rate of 250 mL/
minute for 2 minutes, followed by 4% paraformaldehyde
in 0.1 M phosphate buffer (pH 7.4) at 4°C at a rate of
250 mL/minute for 10 minutes. The flow rate was then
reduced to 100 mL/minute for 50 minutes. The animal
was then perfused with 5% sucrose in 0.1 M phosphate
buffer (pH 7.4) to remove as much fixative as possible.
The brain was blocked stereotaxically, extracted from
the skull and cryoprotected in a solution containing 10%
glycerol and 2% dimethyl sulfoxide (DMSO) for 1 day,
followed by 20% glycerol and 2% DMSO for 3 days. The
fixed brain was then frozen using the isopentane
method [35] and stored at -70°C until sectioning. Frozen
sections were cut in the coronal plane at a thickness of
30 μm with a sliding microtome and placed into a cryo-
protectant tissue-collecting solution (30% ethylene gly-
col, 25% glycerin in 0.05 M sodium phosphate buffer).
The sections were stored at -80°C until they were used
for immunohistochemistry.
Additionally, tissue from one adult rhesus macaque
(Macaca mulatta) whose perfusion included glutaralde-
hyde was used for anti-g-aminobutyric acid (anti-GABA)
immunostaining. Briefly, the perfusion consisted of 0.9%
sodium chloride at a rate of 250 mL/minute for 2 min-
utes, followed by 4% paraformaldehyde/0.1% glutaralde-
hyde at a rate of 250 mL/minute and finally 4%
paraformaldehyde/0.1% glutaraldehyde at a rate of 100
mL/minute for 50 minutes. Tissue was blocked and sec-
tioned in a manner similar to that described for the
cynomolgus macaques.
Mouse tissue
Two adult male C57BL/6 mice were perfused according
to the methods described above for the cynomolgus
macaque tissue, with an initial flow rate of 6 mL/minute
followed by a flow rate of 4.75 mL/minute to account
for the animal’s smaller size. Tissue was cryoprotected
in 10% glycerol and 2% DMSO for 1 day, followed by
20% glycerol and 2% DMSO for 2 days, and was sec-
tioned on a sliding microtome at 30 μm as previously
described for the monkey tissue.
Immunohistochemistry
Free-floating macaque brain sections were processed
using methods employed and described previously
[34,36,37]. Serial sections were used for immunohisto-
chemistry using samples from each subject individu-
ally. Briefly, 30-μm-thick coronal sections from the
brain were taken from storage, placed into nets and
then washed (3 × 10 minutes with 0.1 M phosphate-
buffered saline (PBS)). The following steps were fol-
lowed with agitation at room temperature, except for
the primary incubation, which was performed at 4°C
with agitation. Prior to primary incubation, the sec-
tions were pretreated with hydrogen peroxide (1.6%
hydrogen peroxide in 0.1 M PBS (Fisher Scientific;
Pittsburg, PA, USA) for 15 minutes to remove endo-
genous peroxidases and reduce background staining.
During incubations, the tissue was maintained in solu-
tion at all times. The sections were blocked for 4
hours using 5% normal mouse serum (Pierce Biotech-
nology; Rockford, IL, USA) in 0.1 M PBS and 0.5%
Triton X-100 (Fisher Scientific; Pittsburg, PA, USA).
The nets were incubated with the primary antibody
(subject plasma) at a dilution of 1:100 in 0.1 M PBS,
2% normal mouse serum and 0.3% Triton X-100 for 40
to 48 hours. The sections were then washed with 2%
normal goat serum (Invitrogen; Carlsbad, CA, USA) in
0.1 M PBS (3 × 10 minutes) and incubated with bioti-
nylated mouse anti-human monoclonal immunoglobu-
lin G (IgG) (Zymed: Carlsbad, CA, USA) in 0.1 M PBS,
2% normal mouse serum and 0.3% Triton X-100 for 1
hour. Sections were then washed with 2% normal goat
serum in 0.1 M PBS (3 × 10 minutes) followed by
incubation for 45 minutes with avidin-biotin-complex
(ABC) peroxidase (Biostain Super ABC/Peroxidase
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Basic Kit; Biomeda: Foster City, CA, USA) incubation
in 0.1 M PBS. Following the first ABC peroxidase
incubation, the sections were washed in 2% normal
goat serum in 0.1 M PBS. The incubation with the sec-
ondary antibody (biotinylated mouse anti-human
monoclonal antibody) was repeated for 45 minutes,
followed by washes with 0.1 M PBS only. The second
ABC peroxidase incubation was for 30 minutes, fol-
lowed by washes with 0.05 M Tris buffer. Next, the
sections were incubated with 3,3-diaminobenzidine
(DAB) (Fisher Scientific) in 0.05 M Tris with 0.04%
hydrogen peroxide for 30 minutes. The sections were
then washed twice with 0.05 M Tris, once with 0.02 M
potassium PBS (KPBS) and stored covered at 4°C in
0.02 M KPBS. Sections were then mounted from phos-
phate buffer onto gelatin-coated slides and dried with
a fan, then placed in a 37°C incubator for 24 hours to
dry. Mouse sections were processed in an identical
manner, except for the substitution of 0.5% for 1.6%
hydrogen peroxide and the additional use of an avidin
and biotin blocking kit (Vector Laboratories; Burlin-
game, CA, USA) prior to incubation in the primary
antibody solution.
Silver nitrate/gold chloride intensification
To increase the signal-to-noise ratio of the immunohis-
tochemical reaction product, a silver nitrate/gold chlor-
ide intensification procedure was followed for
immunohistochemical analysis for those sections stained
with DAB. Intensification was not used for sections
visualized by using fluorescence immunohistochemistry.
Prior to intensification, the slides were defatted in a
mixture of equal parts chloroform and 100% ethanol for
a total of 4 hours. The sections were then hydrated
through graded ethanols and placed in a 37°C incubator
overnight. Following the overnight incubation, the slides
were rinsed with running, deionized water for 10 min-
utes, followed by incubation in a 1% silver nitrate solu-
tion maintained at 56°C with the use of a water bath for
40 minutes. The slides were then rinsed with running,
deionized water for 10 minutes and incubated for 10
minutes in a 0.2% gold chloride solution with agitation
at room temperature. Following a second rinse, the
slides were stabilized in a 5% sodium thiosulfate solution
at room temperature for 15 minutes with agitation, fol-
lowed by an additional rinse in running, deionized water
for 10 minutes. Sections were then dehydrated through
graded ethanols, followed by xylenes, and coverslipped
using DPX mounting medium (Sigma Aldrich; St. Louis,
MO, USA).
Slides were observed by bright-field microscopy on a
Nikon Eclipse E600 (Nikon Americas; Melville, NY,
USA) or a Leica Leitz DMRB microscope (Leica Micro-
systems; Buffalo Grove, IL, USA) and photographed
using the Spot Diagnostic Instruments Digital Camera
System and software (Spot Imaging Solutions; Sterling
Heights, MO, USA). Preliminary identification of the
various cell types was accomplished using morphological
features such as their location, cell body size and den-
dritic configuration.
Fluorescence immunohistochemistry
Since it appeared that the majority of neurons that
demonstrated specific immunoreactivity when incubated
with plasma from individuals with autism had the mor-
phological characteristics of GABAergic neurons, we
carried out analyses designed to confirm this finding.
First, we compared the distribution of the plasma-
stained neurons with libraries of sections stained immu-
nohistochemically for the distribution of glutamic acid
decarboxylase 65 (GAD65) and GAD67, GABA or in
situ hybridization with probes to GABAergic neurons
[34,37]. Second, we carried out studies in which sections
were double-labeled for the presence of plasma-identi-
fied interneurons and GABA immunoreactivity. Finally,
we double-labeled additional sections for plasma-labeled
interneurons and the calcium-binding proteins calbin-
din, parvalbumin and calretinin.
For double-labeling with plasma and anti-GABA, sec-
tions from the glutaraldehyde-fixed macaque brain were
rinsed in PBS, then blocked in 0.2% gelatin, 1% Triton
X-100 and 5% normal donkey serum in 0.1 M PBS for 2
hours, and incubated with plasma from an individual
with autism as well as monoclonal mouse anti-GABA
diluted 1:400 (a gift from Ismo Virtanen) at 4°C for 72
hours. Tissue was then rinsed and incubated in Texas
Red-AffiniPure donkey anti-human IgG (1:100; Jackson
ImmunoResearch; West Grove, PA, USA) and fluores-
cein isothiocyanate-conjugated horse anti-mouse IgG
(1:500; Vector Laboratories) for 2 hours at 4°C. For dou-
ble-labeling with plasma and antibodies directed to cal-
cium-binding proteins (calbindin, parvalbumin or
calretinin), a Tyramide Signal Amplification (TSA) kit
(PerkinElmer; Waltham, MA, USA) was used to enhance
the fluorescent signal obtained from labeling with
plasma. Sections were first rinsed in 0.1 M PBS, pre-
treated with 1% hydrogen peroxide in PBS for 30 min-
utes, rinsed in 0.1 M PBS and then blocked with 0.5%
Triton X-100 and 5% normal mouse serum in 0.1 M
PBS for 4 hours. They were then incubated overnight
with a 1:100 dilution of human plasma in 0.1% Triton
X-100 and 1% normal mouse serum in PBS. Sections
were subsequently rinsed in PBS and incubated in Tris-
NaCl-Tween buffer (TNT) buffer for 15 minutes, fol-
lowed by a 30-minute incubation in TNB buffer (Block-
ing buffer supplied with TSA kit; 0.1 M TRIS-HCl, pH
7.5. 0.15 M NaCl. 0.5% Blocking Reagent), and incu-
bated in a 1:1,000 dilution of biotinylated anti-human
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IgG secondary (Zymed; Carlsbad, CA, USA) for 1 hour.
The secondary antibody was washed away with TNT
buffer, and sections were then incubated in streptavidin-
horseradish peroxidase (included in the TSA kit) diluted
1:100 in TNB buffer for 30 minutes. After being washed
with TNT buffer, sections were incubated in tetra-
methylrhodamine tyramide (PerkinElmer) diluted 1:50 in
amplification diluent for 8 minutes at room tempera-
ture, washed in 0.1 M PBS and incubated overnight in a
solution containing an antibody against calbindin
(Swant; CH-1723 Marly 1, Switzerland), parvalbumin
(Swant) or calretinin (Swant) diluted 1:1,000 in 0.02%
gelatin, 0.1% Triton X-100 and 1% donkey serum in 0.1
M PBS. The next day sections were rinsed in 0.1 M
PBS, incubated in secondary antibody (donkey anti-rab-
bit) diluted 1:200 in 0.1% Triton X-100 and 1% donkey
serum in PBS for 2 hours, rinsed in PBS again and
mounted onto slides and coverslipped with VECTA-
SHIELD HardSet Mounting Medium (Vector Labora-
tories). Fluorescently labeled sections were examined
and photographed using an Olympus FluoView confocal
laser-scanning microscope, and analysis was performed
using FluoView version 3.3 software (Olympus: Ham-
burg, Germany). For identification of labeled cells, we




A series of approximately 10 coronal sections from the
Macaca fascicularis brain were processed for each of
the plasma samples evaluated in this study. Sections
were selected to obtain a sample from each of the fol-
lowing regions: frontal lobe, striatum, amygdaloid com-
plex, hippocampal formation, hypothalamus, thalamus,
cerebellum and primary visual cortex (V1). Because the
complete coronal sections were processed, many addi-
tional cortical and subcortical regions, such as the thala-
mus, were also available for analysis. Neurons
immunoreactive for IgG autoantibodies from individuals
with autism were observed in all brain regions. Regard-
less of the region studied, the neurons tended to be
small and to have the appearance of GABAergic inter-
neurons. To provide a description of the types of stain-
ing patterns we observed, we have selected a few
regions to describe in some detail. In all cases, the stain-
ing that we noted was consistently observed for all of
the plasma samples from children with autism that
demonstrated staining of Golgi cells in the cerebellum.
We did not see this pattern of staining in any of the
plasma samples from children with autism who did not
demonstrate Golgi cell staining or in plasma samples
from age-matched typically developing children from
this study population.
Cerebellum
We previously showed that 21% of plasma samples
taken from children with autism demonstrated selective,
intense immunoreactivity against the Golgi cells of the
cerebellum (Figure 1). In many cases, populations of
basket cells in the molecular layer demonstrated specific,
albeit less intense, immunoreactive staining. There were
no other cell types in the cerebellar cortex that were
recognized by these IgG autoantibodies.
Cerebral cortex (area V1)
We next focused our analysis of the cerebral cortex on
area V1 of the occipital lobe (Figure 2). This cortical
region was selected because of the nature of its well-
characterized cellular neuroanatomy. The pattern of
immunoreactive staining was consistent across all
plasma samples (Figures 2B and 2E). While there was
some heterogeneity in the morphology of labeled neu-
rons, the vast majority of cells appeared to be small, cir-
cular cells with several radiating dendrites. Similar
patterns were detected between the autoantibody-labeled
cells and cells labeled by in situ hybridization with a
probe to GAD67 (Figure 2C) or cells labeled immuno-
histochemically with an antibody to GABA (Figure 2D).
The labeled cells had very similar morphology in all
three preparations. The distribution of labeled cells was
somewhat different, however. With the plasma autoanti-
bodies, there was a clear preponderance of labeled neu-
rons in the superficial layers (I to III), whereas fewer
Figure 1 Photomicrographs illustrating coronal sections
through the macaque monkey cerebellum. (A) Nissl-stained
section illustrating the three major layers of the cerebellum: the
granule cell layer (GCL), the Purkinje cell layer (PCL) and the
molecular layer (ML). The locations of several large Purkinje cells
(asterisks) are shown. (B) Immunoreactivity resulting from exposure
of adjacent section to plasma from a representative child with
autism (age 4 years). Golgi neurons (black arrows) are clearly labeled
and lie adjacent to or below the Purkinje cell layer. Ghost images of
Purkinje cells are marked with asterisks. Lighter, though consistent,
labeling of basket cells (white arrows) was also observed with this
plasma. Only plasma from subjects that provided this level of
staining of the Golgi cells in the cerebellum was used for analysis of
other brain regions. Calibration bar, 100 μm.
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labeled cells were observed in the deep layers (IV to VI).
For the GAD67 and GABA preparations, however, the
distribution of labeled cells was more homogeneous
across all of the cortical layers. In particular, it appeared
that there were relatively few autoantibody-reactive cells
in layer V in comparison to the GAD67- and GABA-
labeled cells. This raised the prospect that the vast
majority of neurons recognized by the autoantibodies
from individuals with autism were GABAergic
interneurons. However, it also appeared likely that these
antibodies were not staining a population of GABAergic
neurons located in the deep cortical layers.
To provide evidence for the proposition that the
plasma labeled cells were GABAergic, an additional
series of sections through area V1 were double-labeled
with plasma and with anti-sera to GABA (Figure 3).
On the basis of evaluation using the confocal laser
microscope, we confirmed that essentially all
Figure 2 Photomicrographs illustrating coronal sections through primary visual cortex (V1) of the macaque monkey brain. (A) Nissl-
stained section showing the lamination pattern (cortical layers I to VI) of neurons in this region. (B) Staining of V1 with plasma from one child
with autism (age 6 years). Note that in this panel and Figure 2E, the highest numbers of labeled neurons are located in the superficial layers (I to
III). (C) Section through area V1 demonstrating in situ hybridization with a probe to glutamic acid decarboxylase 67 (GAD67). The brown reaction
product illustrates neurons that are GABAergic. (D) Very similar representation of GABAergic neurons identified immunohistochemically with a
monoclonal antibody to g-aminobutyric acid (GABA). (E) Staining very similar to that shown in Figure 2B of plasma from another child with
autism (age 5 years). (F) Section through area V1 that was reacted with plasma from a typically developing child (age 5 years). While there is
light, nonspecific background staining that resembles the distribution of Nissl-stained cell bodies, there is no specific labeling of GABAergic
neurons. Calibration bar, 100 μm.
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autoantibody-reactive cells were double-labeled for
GABA. We also confirmed that a sizable number of
GABA-positive neurons were not immunoreactive with
the plasma. Many of these single-labeled GABAergic
neurons were located in the deep layers of the cortex.
Because only a subset of GABA-positive neurons was
labeled by autoantibody-containing plasma, we wanted
to get a sense of which populations of GABAergic neu-
rons were being labeled. While it was beyond the
scope of the current paper to do an exhaustive, quanti-
tative analysis with double-labeling, we did double-
label sections through area V1 with plasma and antibo-
dies directed against the calcium-binding proteins cal-
bindin, parvalbumin and calretinin. We determined
that plasma-labeled cells were not exclusively labeled
by any one of these proteins expressed in GABAergic
neurons. Rather, it appears that the immunoreactive
cells were most commonly labeled by calbindin, but
not all calbindin-labeled cells were labeled by the auto-
antibodies (Figures 4A to 4C). Autoantibody-labeled
cells less commonly expressed parvalbumin (Figures
4D to 4F), and labeling with calretinin in plasma-
labeled cells was rare (Figures 4G to 4I).
Cerebral cortex (posterior cingulate cortex)
We have previously provided a detailed cytoarchitec-
tonic analysis of the posterior and retrosplenial regions
of the cingulate cortex [38]. Figure 5 shows a coronal
section through this region that includes areas 29, 30
and 23. As in area V1, autoantibody-reactive cells are
distributed throughout all layers of these cortical
regions, with a slight predominance in superficial layers
I to III. The white matter deep within these cortical
areas (Figure 5B) has a mottled appearance. This is due
to the labeling of a population of glial cells by the
plasma. We describe these cells below.
Hippocampal formation
As illustrated in Figure 6, there are populations of
plasma-labeled cells in the hippocampus and dentate
gyrus. We have previously evaluated the distribution of
GABAergic neurons in the macaque monkey hippocam-
pal formation [36,37]. The population of autoantibody-
positive cells in the hippocampal formation was morpho-
logically heterogeneous. In the CA3 region of the hippo-
campus (Figures 6A and 6B), labeled neurons were
located mainly in the stratum oriens, stratum radiatum
and stratum lacunosum-moleculare. Relatively few
labeled neurons were observed in the pyramidal cell layer
or the stratum lucidum. The dendrites of labeled neurons
were well-stained and often had a horizontal orientation,
particularly in stratum oriens and stratum lacunosum-
moleculare. In the dentate gyrus (Figures 6C and 6D), the
majority of labeled cells were located in the polymorphic
layer. Again, they had variable morphologies. Some
appeared to be typical dentate basket cells, but others
had dendrites that were mainly oriented parallel to the
granule cell layer. There were a few small, round, labeled
cells in the molecular layer of the dentate gyrus.
Amygdaloid complex
Autoantibody-labeled cells were distributed throughout
all nuclei of the amygdala (Figure 7). Both the distribu-
tion and the appearance of the labeled neurons
resembled GABAergic neurons based on our previous
evaluation of GABA, GAD and parvalbumin labeling
[34,37]. We have illustrated the distribution of autoanti-
body-labeled cells in and around the central nucleus of
the amygdala (Figure 7). We had previously found that
GABAergic neurons in the central nucleus do not stain
well using antibodies directed against GABA [34]. How-
ever, in situ hybridization with probes to GAD65 or
GAD67 demonstrated a very high density of GABAergic
neurons spread more or less uniformly across the lateral
and medial divisions of the nucleus. Interestingly, auto-
antibody labeling consistently demonstrated a high den-
sity of immunoreactive neurons with prominent
dendritic staining located in the medial division of the
Figure 3 Fluorescence confocal photomicrographs of double-
labeling with plasma from a representative child with autism
(age 5 years) and an antibody directed at GABA. (A) GABA
immunoreactivity in area V1 (green). (B) Immunoreactivity of V1
with plasma from a child with autism (red). (C) Merged images from
Figures 3A and 3B showing several double-labeled cells (yellow).
The vessels have been labeled (V) to aid in orientation with Figure
3D. (D) Schematic of the same region shown in Figures 3A to 3C,
with cells coexpressing GABA and plasma immunoreactivity,
depicted as yellow circles, GABAergic cells without plasma
immunoreactivity, depicted as green hexagons, and a single GABA-
negative, plasma-positive cell, depicted as a red star. The vessels
have been labeled (V) to aid in orientation with Figure 3C.
Calibration bar, 100 μm.
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nucleus. The lateral division, in contrast, demonstrated
rather meager neuronal labeling reminiscent of the stria-
tal labeling (see below).
Striatum
We also observed autoantibody labeling within the cau-
date nucleus of the striatum (Figure 8), although there
were very few labeled neurons in this region. All of the
positively labeled cells were small (approximately 8 to
10 μm in diameter), with round cell bodies and short
dendrites radiating in all directions (Figure 8B). When
we examined sections stained immunohistochemically
with an antibody to GABA (Figure 8C), it was clear that
the autoantibody-labeled neurons resembled one of the
classes of neurons demonstrating GABA immunoreac-
tivity (Figure 8C). However, larger GABA-immunoreac-
tive neurons that were not stained with the
autoantibodies were also present.
White matter
We did not observe any autoantibody-stained profiles
within major fiber bundles such as the corpus callosum
Figure 4 Fluorescence confocal photomicrographs of double-labeling with plasma from a representative child with autism and
antibodies directed toward calcium-binding proteins in area V1. (A to C) Immunoreactivity of (A) the autism (AU)-specific autoantibodies,
(B) calbindin and (C) the merged image showing that several cells are colabeled (arrows), but that not all AU immunoglobulin G (IgG)-labeled
cells express calbindin (arrowheads). Double-labeling with plasma from (D) a autoantibody-positive child with autism and (E) anti-parvalbumin
shows that some AU IgG-labeled cells express parvalbumin (arrows), while most do not (arrowheads). (G to I) AU immunoreactivity (G) rarely
occurs in cells that express calretinin (H) with no co-localization evident (I). Arrowheads point to cells that are labeled by the autoantibody, but
not by anti-calretinin (I). Calibration bar, 100 μm.
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or the anterior commissure. However, in the white mat-
ter just subjacent to the neocortex, we did see reactive
profiles that resembled microglial cells (Figure 9). Since
we saw no evidence of astroglial staining in the cerebel-
lum (Bergmann glial cells) or labeling of glial end-feet
along the vasculature, these subcortical microglial cells
appear to be the only non-neuronal cells immunoreac-
tive with the autoantibodies. Interestingly, Butovsky et
al. [39] recently demonstrated that exposure of micro-
glia to the proinflammatory cytokine interferon-g
induced them to express both GABA and GAD67.
Microglia also express GABAB receptors [40].
Mouse tissue
Given the limited supply of plasma from the participants
involved in this study, we were unable to carry out an
exhaustive comparison of staining in the monkey and
mouse brain. However, we were able to determine that
the neurons that were morphologically characterized as
interneurons were also labeled in various regions
throughout the mouse brain. As illustrated in Figure 10,
there were populations of immunoreactive neurons scat-
tered throughout the neocortex. Many of these cells had
substantial dendritic labeling (Figure 10D), and all
resembled classes of interneurons. Immunoreactive neu-
rons were observed in the hippocampus, amygdala and
other brain regions that were also noted in the monkey
brain (not shown). Interestingly, while the Golgi neurons
of the mouse cerebellum were lightly immunoreactive,
the intensity of staining was not nearly as striking as in
the monkey brain or as intensely labeled as neurons
observed in other brain regions. We intend to carry out
a more exhaustive species comparison in a future study.
Discussion
We previously reported that plasma from children with
autism contains autoantibodies that are reactive to cere-
bellar Golgi cells [26]. The current study expands our
earlier observations by exploring the pattern of immu-
nohistochemistry in additional brain regions. We have
demonstrated that the plasma from children with ASD
contains antibodies that are reactive to neurons
throughout the brain that are invariably GABAergic
interneurons. We have also determined that not all
GABAergic neurons are immunopositive, although we
have not yet been able to determine in detail which
categories of GABAergic neurons are positive for the
plasma staining.
GABAergic cells form a heterogeneous population of
neurons that are unevenly distributed in all layers of the
monkey neocortex [41]. At least 20% of the neurons in
the primary visual cortex are GABAergic interneurons
[42], and the distribution in the monkey brain is quite
similar to that in the human brain [43]. The plasma
from children with autism allowed us to identify popula-
tions of cells in all layers of the cerebral cortex, with a
slight preponderance in superficial layers. Colocalization
studies using a monoclonal antibody to GABA revealed
that the plasma from children with ASD appeared to
recognize GABAergic interneurons in V1. There were
fewer plasma-labeled cells in the deep layers of cortex
relative to GABA staining. Double-labeling with plasma
and antibodies toward the calcium-binding proteins cal-
bindin, parvalbumin and calretinin revealed that plasma-
labeled cells commonly expressed calbindin. The auto-
antibody-positive cells expressed parvalbumin less com-
monly and calretinin only rarely. The distribution of
GABAergic interneurons that colocalize one of these
calcium-binding proteins is variable from one cortical
area to the next, and certain interneuron types can colo-
calize more than one of the proteins [44-47]. Defelipe
[48] provided a detailed description of the correspon-
dence of specific interneuron types and immunoreactiv-
ity for a calcium-binding protein in the neocortex. In
general, parvalbumin is associated with chandelier and
large basket cells; calretinin is associated with bipolar,
double-bouquet and Cajal-Retzius cells; and calbindin is
associated with double-bouquet, neurogliaform, Marti-
notti and, in rare cases, Cajal-Retzius cells. This implies
that the plasma autoantibodies affect neurons harboring
calbindin more than those colocalizing the other cal-
cium-binding proteins. However, it is not possible at
this time to predict the specific functional significance
of targeting these specific classes of interneurons. The
question why some GABAergic interneurons are identi-
fied by the plasma autoantibodies and others is not very
difficult to speculate on, given that the antigen is not
Figure 5 Photomicrographs of coronal sections through the
posterior cingulate cortex of the macaque monkey. This level
includes areas 29, 30 and 23. (A) Nissl-stained section showing the
laminar pattern of posterior cingulate cortex located just dorsal to
the corpus callosum (cc). The layers of cortical area 23 are marked I
to VI. (B) Immunostaining with plasma from a representative child
with autism. As in the primary visual cortex, the most numerous
labeled neurons are located in the superficial layers (I to III),
although immunopositive neurons are located throughout all layers.
This pattern was recapitulated in all cortical areas. Labeled cells
were not observed in the cc, although apparent positive cells were
observed in the subcortical white matter. Calibration bar, 250 μm.
Wills et al. Molecular Autism 2011, 2:5
http://www.molecularautism.com/content/2/1/5
Page 9 of 14
known. However, recent neuronal transcriptome studies
[49,50] have made it abundantly clear that tens to hun-
dreds of proteins differentiate neuronal classes. Given
the distinct morphological features of interneurons, it is
highly likely that different classes of GABAergic neurons
express different profiles of proteins and that one or
more of these are being identified by the plasma
autoantibodies.
Our finding that some children with autism produce
autoantibodies directed against GABAergic neurons is
all the more interesting, given the other indications that
ASDs may be highly related to impaired GABAergic
Figure 6 Photomicrographs of the CA3 region of the hippocampus and the dentate gyrus of the macaque monkey. (A) Nissl-stained
section showing the major layers of the CA3 region of the hippocampus. Deep to superficial layers include so, stratum oriens; pcl, pyramidal cell
layer; sl, stratum lucidum, sr, stratum radiatum, sl-m, stratum lacunosum-moleculare. (B) Section of the CA3 region of the hippocampus stained
immunohistochemically with plasma from a representative AU subject. Numerous labeled neurons are observed in the stratum radiatum (black
arrows) and the adjacent stratum lacunosum-moleculare (open arrows). Only background level staining is observed in the pyramidal cell layer,
but there are a variety of labeled neurons in stratum oriens (white arrows). (C) Nissl-stained section showing the layers of the dentate gyrus.
Layers include pl, polymorphic layer; gcl, granule cell layer; and ml, molecular layer. (D) Section of the dentate gyrus stained
immunohistochemically with plasma from a child with autism. Numerous labeled neurons (black arrows) are shown in the polymorphic cell
layer, whereas fewer positive cells (open arrows) are shown in the molecular layer. Calibration bars, 100 μm. The bar in B applies to A, and the
bar in D applies to C.
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function. Previous studies have suggested that there is a
depression of the GABAergic system, potentially due to
altered GABA receptors and reduced GAD, in the etiol-
ogy and maintenance of ASD [51-53]. It has also been
proposed that suppression of GABAergic function in the
brain of individuals with ASD may result in compensa-
tory mechanisms and increased activation of additional
GABAergic receptor subtypes [54]. The potential imbal-
ance of excitatory and inhibitory neurotransmission in
autism could influence cortical networks that control
social behaviors and neuromodulatory systems [55].
Interestingly, a reduction in GABAergic activity is also
capable of causing epilepsy, which has been reported in
up to one-third of individuals with ASD [52,56-60].
While the participants in the present study were not
assessed for epileptic seizure activity, this would be of
great interest for future longitudinal studies.
Figure 7 Photomicrographs of the dorsal portion of the
amygdala of the macaque monkey. (A) Nissl-stained section of
the dorsolateral portion of the amygdala. Much of the field is taken
up by the central nucleus that can be divided into lateral (CEl) and
medial (CEm)divisions. The basal nucleus (B) is located just ventral
to the central nucleus. The substantia innominata (SI) is located just
dorsal to the central nucleus. (B) Immunohistochemical staining of
the amygdala using plasma from a representative child with autism.
Labeled neurons are observed throughout all nuclei of the
amygdala. In the central nucleus, the lateral nucleus has relatively
few labeled neurons, whereas the density, size and dendritic
staining of cells is much more prominent in the medial portion of
the central nucleus. Calibration bar, 250 μm.
Figure 8 Photomicrographs of the caudate nucleus of the
macaque monkey. (A) Nissl-stained section showing the density of
striatal neurons in this region. (B) Phase-contrast photomicrograph
illustrating small (approximately 10 μm in diameter), stellate neurons
stained with plasma from a representative AU subject. (C) Section
though the caudate nucleus reacted with a monoclonal antibody to
GABA. Immunoreactivity is associated with numerous axonal
varicosities as well as a variety of neuronal cell types. The small,
stellate cell type observed by plasma immunohistochemical staining
is also shown in the GABA preparations (black arrow). Other, larger
GABAergic neurons (white arrow) can also be observed. Calibration
bar, 10/100 μm.
Figure 9 Cellular profiles are also shown in the subcortical
white matter in sections in which plasma stained GABAergic
neurons. (A) Phase-contrast photomicrograph of AU-
immunoreactive, presumed microglial cells located in the white
matter deep within the somatosensory cortex. (B) Similar region
from a section reacted with plasma from a representative typically
developing child in which no microglial labeling is observed.
Calibration bar, 25 μm.
Figure 10 Illustrations of plasma staining of the mouse
somatosensory cortex. (A) Nissl-stained section of the mouse
somatosensory cortex. Layers I to VI are indicated on the right-hand
side of the image. (B) Autoantibody staining of a section adjacent
to the Nissl-stained section depicted in A with plasma from a
representative AU subject. There are numerous immunoreactive
neurons (arrows) scattered throughout all layers of the cortex.
Calibration bar in B = 250 μm and applies to A as well.
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In a study by Fatemi and colleagues [61], GAD, which
converts glutamate to GABA and is a marker commonly
used to identify GABAergic neurons, was found to be
reduced by 48% to 61% in the parietal cortex and cerebel-
lum in five individuals with autism relative to eight con-
trols. More recent studies by Fatemi and colleagues [62]
have found downregulated expression of various combi-
nations of GABAA receptor subunits in the parietal cor-
tex, cerebellum and superior frontal cortex in the brains
of individuals with autism. These investigators also
reported alterations of GABAB receptor subunit expres-
sion in the same areas of the brain [63]. Yip and collea-
gues [64,65] reported increased levels of GAD67 mRNA
levels in cerebellar interneurons but decreased levels in
Purkinje cells. Blatt et al. [66] examined the distribution
and density of GABAergic, serotonergic, cholinergic and
glutamatergic receptors in the hippocampus of indivi-
duals with ASD and typically developing controls. The
only receptor system found to be significantly reduced in
individuals with ASD was the GABAergic system [66].
Decreased GABA levels have also been reported in the
platelets of children with ASD [67].
While it is intriguing that some children with autism
demonstrate autoantibodies that are immunoreactive to
central nervous system GABAergic neurons, it is not at
all clear whether these antibodies play a pathophysiolo-
gical role in the etiology of autism or are an epipheno-
menon indicative of some other pathological process. In
order for the systemic antibodies to interact with central
nervous system neurons, they must be able to reach
their antigenic targets. As antibodies do not readily
cross the blood-brain barrier, a breach would have to
occur to allow access. Cytokines in the peripheral circu-
lation or cytokines produced by central nervous system
cells are capable of altering the blood-brain barrier
through endothelial cell activation [68]. Disturbances to
the blood brain-barrier can be caused by a number of
other factors, including extreme stress, subclinical infec-
tion and even nicotine or epinephrine exposure [69-71].
In studies by Diamond and colleagues [72,73] in which
an animal model of systemic lupus erythematosus (SLE)
was explored, antibodies directed against the N-methyl-
D-aspartate receptor were able to enter the brain follow-
ing exposure to either lipopolysaccharide or norepi-
nephrine. These antibodies not only produced
neuropathological changes in the hippocampus or amyg-
dala, respectively, but also led to impaired memory
function or increased anxiety.
If we presume that the anti-GABAergic neuron anti-
bodies produced by children with autism can gain entry
to the brain, there are several possible mechanisms
through which they may influence cell function. First,
autoantibodies may act as an agonist or a receptor
ligand, causing excessive receptor stimulation. This
phenomenon has been demonstrated in approximately
27% of patients with epilepsy and 30% of individuals
with SLE, as well as in some patients with encephalitis,
in whom various autoantibodies to the glutamate recep-
tor have been described [74]. Further, both human and
animal studies have demonstrated that the described
glutamate receptor autoantibodies are pathologic, bind-
ing to neurons with a unique ability to activate their
glutamate receptor antigen and leading to neuronal
death, either through excitotoxicity or by complement
fixation independent of receptor activation [74-76].
While a decreased number of neurons has been
reported in the amygdala [77] and in the fusiform gyrus
[78] of postmortem cases of autism, it is not yet clear
whether there is a preferential loss of any particular
category of neurons, such as GABAergic interneurons.
The second possibility for autoantibody-induced
pathology is through antibody-mediated inhibition of a
critical receptor, ligand or pathway. This would be simi-
lar to the pathologic mechanism through which the
autoantibodies to thyroglobulin, thyroid peroxidase and/
or the thyroid-stimulating hormone receptor function in
Hashimoto’s thyroiditis [79]. Whether through excita-
tion or inhibition, autoantibody-mediated changes are
capable of resulting in a number of permanent changes,
including inhibition-excitation imbalance, altered neural
circuitry and changes in receptor numbers and distribu-
tion. Finally, it is possible that the autoantibody directly
induces cell and tissue destruction through complement
activation such as that seen in patients with SLE [80].
Each of the above-discussed mechanisms, either indivi-
dually or in concert, is a possibility with respect to the
autoantibodies described herein. However, additional
studies, including an animal model, are needed to deter-
mine the pathologic relationship between these autoanti-
bodies and ASD.
Conclusions
It is of great interest that autoantibodies from a subset
of children with ASD are directed against GABAergic
neurons with identical patterns of staining distributed
throughout the central nervous system. This study raises
several issues, including the identity of the target anti-
gen that these antibodies recognize and the reason for
the selectivity of this response. Knowledge about what
differentiates immunopositive from immunonegative
GABAergic neurons may provide further clues regarding
the characteristics of the autoantigen and proteomic stu-
dies currently underway to determine the identity of the
target protein. One additional point to address is
whether the presence of these GABAergic neuron-speci-
fic autoantibodies is pathologically significant or merely
an epiphenomenon. Ultimately, the potential mechan-
isms and/or exposures that lead to the generation of
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these autoantibodies, the timing at which they occur,
and their pathologic significance require further
consideration.
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